Category: Pharmaceutical Industry
-
Unified Patent Court injunction in 10x Genomics v. NanoString could be reinstated as EPO Opposition Division upholds patent in ‘slightly amended form’
Context: The Unified Patent Court (UPC) opened its doors on June 1, 2023, and only a few months later, in September 2023, 10x Genomics won a preliminary injunction against rival NanoString in the Munich Local Division (LD). NanoString nearly went out of business as a result of that loss, but apparently found an acquirer. The…
-
Genevant Sciences and Arbutus Biopharma file mRNA vaccine patent infringement lawsuits against Moderna in UPC, Switzerland, Japan, Canada
The companies are seeking monetary relief and injunctions against Moderna’s Spikevax® and mRESVIA® vaccinations, among others, alleging that the company is infringing their lipid composition patents in 30 different countries.
-
AstraZeneca expands cancer drug patent enforcement campaign in U.S., seeks preliminary injunctions
AstraZeneca has filed four separate complaints against generic drugmakers Cipla, Sandoz, Natco, and Zydus in the United States District Court for the District of New Jersey.
-
Catalyst and Teva Pharmaceuticals settle patent dispute over rare-disease drug, but fight for orphan treatment not over yet
Nasadaq-listed Catalyst sees shares rise by 18% following the settlement, which grants Teva a license from February 2035.
-
UPC’s Court of Appeal throws out Alexion’s appeals against Amgen and Samsung Bioepis over validity doubts, reveals €100M value of each dispute
The UPC’s Court of Appeal rejects Alexion’s appeals of decisions to deny preliminary injunctions against Amgen and Samsung Bioepis, where the value of the dispute was set at €100M for each case.
-
Japan’s Nippon Shinyaku vows to fight on in U.S. drug dispute against Sarepta Therapeutics, despite heavy $115 million blow
The Japanese pharma company initiated the drug patent litigation in 2021, but the case eventually boomeranged and a District of Delaware verdict last week ultimately handed Sarepta the win.
-
AstraZeneca defends record patent invalidation claims in China
The UK pharma giant has defeated 33 invalidation claims brought by Chinese generics manufacturers against crystal form patents related to its highest-selling diabetes drug.
-
Pfizer brought UPC revocation action 9 seconds after midnight on grant date, argues Glaxo jumped the gun with infringement filing
Pharmaceutical giants GlaxoSmithKline and Pfizer are embroiled in an interesting UPC venue fight that involves questions of timing.
-
China’s Supreme People’s Court settles mRNA patent, trade secrets litigation under President Xi’s new ‘Fengqiao’ dispute model
Chinese courts are imposing mediation on more and more cases under the new order, including those involving patent infringement.
-
Northwestern University amended license agreement with inventors’ startup, now suing Moderna in Delaware over LNP patents
Northwestern University is suing Moderna over lipid nanoparticle (LNP) patents.